NeuroVice

Executive Summary

NeuroVice is a US-based medical device company founded in 2019 by a patient with lived experience of seizures. The company addresses a critical unmet need in epilepsy care: preventing tongue biting and oral trauma during seizures while maintaining airway management. Its flagship product, PATI® (Protector Against Tongue Injury), is an FDA-cleared, single-use oral device designed to reduce injury risk and improve patient safety. The device is positioned to enhance the standard of care for millions living with seizure disorders, particularly in emergency and home settings. NeuroVice operates in the neuroscience and digital health categories, with operations based in Cambridge, Massachusetts. Despite its innovative product and FDA clearance, the company remains privately held with limited public financial or operational data, suggesting an early commercial stage. The market opportunity for PATI is significant given the prevalence of epilepsy and seizure-related injuries. However, the company faces challenges in adoption, reimbursement, and scaling distribution. NeuroVice's patient-founded origin provides authentic insight, but the lack of disclosed funding, revenue, or pipeline details makes it difficult to assess traction. Conviction in the company is moderate, hinging on successful commercialization and ability to secure partnerships. If the company can expand its product line or demonstrate clinical outcomes beyond safety, it could capture a niche but valuable segment of the neurological device market.

Upcoming Catalysts (preview)

• Q4 2026Commercial distribution partnership for PATI60% success
• Q3 2026Series A funding round to scale operations50% success
• Q1 2027Expansion of FDA clearance to include additional seizure indications40% success